{"id":"W4411131729","doi":"10.1017/s109285292510031x","title":"Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease","year":2025,"lang":"en","type":"review","venue":"CNS Spectrums","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation; Queen's University","funders":"Department of Psychiatry, University of Toronto; Health Resources and Services Administration; Substance Abuse and Mental Health Services Administration; Allergan; National Institutes of Health; Bausch Health; National Natural Science Foundation of China; University of Cambridge; Canadian Institutes of Health Research; Sunovion; Eisai; Purdue University; H. Lundbeck A/S; Patient-Centered Outcomes Research Institute; University of Toronto; Biogen; Novo Nordisk; Sanofi; National Institute of Mental Health; Pfizer","keywords":"Parkinson's disease; Medicine; Receptor; Glucagon-like peptide-1; Glucagon-like peptide 1 receptor; Glucagon; Pharmacology; Disease; Agonist; Endocrinology; Internal medicine; Diabetes mellitus; Insulin; Type 2 diabetes","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001015217,0.0004029686,0.001242593,0.0001555994,0.0001014887,0.00003200637,0.0001106425,0.00009390016,0.00009053254],"category_scores_gemma":[0.00003402148,0.0002317447,0.000796716,0.000175179,0.00008227442,0.0000380113,0.00005594664,0.00005712591,0.00001869076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003104048,"about_ca_system_score_gemma":0.000293875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001251622,"about_ca_topic_score_gemma":0.00001579424,"domain_scores_codex":[0.9986662,0.00004447656,0.0004156412,0.0004495732,0.0001536706,0.0002704177],"domain_scores_gemma":[0.9987538,0.0002412489,0.0002497121,0.0005983365,0.00002879202,0.0001280831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008285561,0.00053677,0.00007509239,0.01571553,0.001617643,0.000005925765,0.00002834823,8.769602e-8,2.382387e-7,0.001143681,0.005393039,0.9754008],"study_design_scores_gemma":[0.001155777,0.0008748409,0.000234507,0.008032416,0.01215314,0.000001332902,0.00001767511,0.000005515209,0.000005328863,0.0001203171,0.9772347,0.0001644002],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004710583,0.9917237,0.00005884489,0.0004442507,0.0004904504,0.005744325,0.0001470696,0.00004411907,0.001300111],"genre_scores_gemma":[0.00004802256,0.9437229,0.0002897267,0.00003543834,0.000233748,0.001763243,0.0006703724,0.0000374682,0.05319909],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9752364,"threshold_uncertainty_score":0.9450276,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03388562398677773,"score_gpt":0.3256993208346544,"score_spread":0.2918136968478766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}